Immunotherapy Developers, Clinical Researchers Continue to Seek New Dx Strategies – GenomeWeb

Posted by on April 10, 2019 3:03 am
Tags:
Categories: Crispr Articles

Source: Immunotherapy Developers, Clinical Researchers Continue to Seek New Dx Strategies – GenomeWeb

NEW YORK (GenomeWeb) – As recognition has grown that existing immunotherapy biomarkers like PD-L1, microsatellite instability, and tumor mutational burden predict only some of the response variability seen in this new and highly popular class of drugs, pharma firms and independent researchers are broadening their attention, hoping to capture new features of the complex interaction between a cancer and the human immune system that can guide which patients to tre

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Published at Tue, 09 Apr 2019 19:45:45 +0000

< Immunotherapy Today home